CIDARA THERAPEUTICS INC. - COMMON STOCK

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

05 Apr 2024 14:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

06 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

12 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

29 Jan 2024 15:30:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

22 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

07 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

06 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

30 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Named as a San Diego Metro Area Top Workplace

20 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

02 Nov 2023 15:15:24 By Nasdaq GlobeNewswire

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

13 Oct 2023 09:34:14 By Nasdaq GlobeNewswire

Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

11 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

29 Sep 2023 15:51:53 By Nasdaq GlobeNewswire

Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023

27 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023

07 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference

06 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development

16 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

03 Aug 2023 15:08:15 By Nasdaq GlobeNewswire